As GLP-1 Use Surges, Clinicians Weigh Benefits and Risks (Medscape)

With obesity rates surging, GLP-1 receptor agonists (GLP-1 RAs) are showing promise as effective weight-loss treatments, with significant results for many patients. Experts like Dr. Andres Acosta emphasize the need for precision medicine to identify the best responders based on obesity phenotypes such as “Hungry Gut” and “Hungry Brain.” Dr. Daniel Drucker highlights the varying patient responses to these drugs, while Dr. Marc-Andre Cornier stresses their use alongside lifestyle changes, such as high-quality diets and resistance exercises, to mitigate potential risks like muscle loss. Despite their efficacy, GLP-1 RAs face challenges, including side effects, high costs, and patient discontinuation rates, underscoring the need for careful application to combat the obesity crisis effectively.